Presentation is loading. Please wait.

Presentation is loading. Please wait.

“Learning curve” group= 10 pts with mBrCa (ER+ or ER-) who are beginning a new therapy ~5 pts with ≥5CTC/7.5 ml Group 1 5 CTC evaluable pts* with ER+ mBrCa.

Published byNickolas Stevenson Modified over 9 years ago

Similar presentations

Presentation on theme: "“Learning curve” group= 10 pts with mBrCa (ER+ or ER-) who are beginning a new therapy ~5 pts with ≥5CTC/7.5 ml Group 1 5 CTC evaluable pts* with ER+ mBrCa."— Presentation transcript:

1 “Learning curve” group= 10 pts with mBrCa (ER+ or ER-) who are beginning a new therapy ~5 pts with ≥5CTC/7.5 ml Group 1 5 CTC evaluable pts* with ER+ mBrCa who are beginning a new therapy:  If CTC-ETI has been successfully generated in 5/5 pts  If CTC-ETI has been successfully generated in ≤ 4/5 pts Proceed to multi-institutional, multi-blood draw pilot study Stage 1 Stage 2 Group 2 5 additional CTC evaluable pts* with ER+ mBrCa who are beginning a new therapy. Combining the findings from group 1+2:  If CTC-ETI has been successfully generated in 6/10 pts  If CTC-ETI has been successfully generated in 4-5/10 pts  If CTC-ETI has been successfully generated in ≤3/10 pts  STOP and reconsider methods Group 3 5 CTC additional evaluable pts* with ER+ mBrCa who are beginning a new therapy. Combining the findings from group 1+2+3 (total sample size 15 CTC-evaluable pts):  If CTC-ETI has been successfully generated in ≥9/15 pts  If CTC-ETI has been successfully generated in ≤8/15 pts  STOP and reconsider methods * ≥5CTC/7.5ml WB Figure S1. Clinical trial study design

2 MDA-MB-231 MCF-7* Sk-Br-3MDA-MB-231MCF-7 BT-474 MDA-MB-231MCF-7*MDA-453 BT-474 MCF-7 Sk-Br-3 MDA-MB-231 MCF-7* Figure S2. Examples of biomarker staining of cultured human breast cancer cell lines after spike and capture from normal human blood using the CellSearch® system. A semi-quantitative scale was established based on relative expression of each biomarker: negative (0), weak (1+), intermediate (2+), and high (3+). *hormone depleted condition. ER BCL-2 HER-2 Ki67 0 1+ 2+ 3+ Staining Intensity

3 Fig. S3. Demonstration of appropriate antibody staining of cultured human breast cancer cells with known positive and negative biomarker expression after spike and capture from normal human blood using the CellSearch ® System. A: ER staining for MCF-7 and Sk-Br-3. B: BCL- 2 staining for MCF-7 and Sk- Br-3. C: HER2 staining for Sk-Br-3 and MCF-7. D: Ki-67 staining for MCF-7.

4 % ER pos CTC 86% 0% Composite DAPI Cytokeratin-FITC ER-PE CD45-APC A. Hormone depleted MCF-7 +Anti-ER Ab + no Ab Sk-Br-3 +Anti-ER Ab + no Ab

5 % BCL-2 pos CTC 84% 0% Composite DAPI Cytokeratin-FITC BCL2-PE CD45-APC B. MCF-7 +Anti-BCL-2 Ab + no Ab Sk-Br-3 +Anti-BCL-2 Ab + no Ab

6 % HER2 pos CTC 100% 0% Composite DAPI Cytokeratin-FITC HER2-PE CD45-APC C. MCF-7 +Anti-HER2 Ab + no Ab Sk-Br-3 +Anti-HER2 Ab + no Ab

7 % Ki67 pos CTC 42% 0% Composite DAPI Cytokeratin-FITC Ki67-PE CD45-APC D. MCF-7 +Anti-Ki67 Ab + no Ab

8 Figure S4. Composite “CTC-Bio_Score” for different cell lines. A: Hormone deplete MCF-7 cells (Luminal-type). B: MDA-MB-231 ( Basal-like type). C: Sk-Br-3 (HER2 positive) Composite DAPI Cytokeratin-FITC Marker-PE CD45-APC Anti-ER Anti-BCL-2 Anti-HER2 Anti-Ki67 A. >10% % Pos >10% 1% >10% Assigned Bio-Points 0 0 1 2 Total CTC-ETI Bio-Score 3

9 Composite DAPI Cytokeratin-FITC Marker-PE CD45-APC Anti-ER Anti-BCL-2 Anti-HER2 Anti-Ki67 B. 0% % Pos 1-10% 0%0% >10% Assigned Bio-Points 6 1 0 2 Total CTC-ETI Bio-Score 9

10 Composite DAPI Cytokeratin-FITC Marker-PE CD45-APC Anti-ER Anti-BCL-2 Anti-HER2 Anti-Ki67 C. 0% % Pos 0% >10% Assigned Bio-Points 6 2 2 2 Total CTC-ETI Bio-Score 12

11 Composite DAPI Cytokeratin-FITC Marker CD45-APC No nuclear positivity (0) Strong nuclear positivity (2+; 3+) Weak nuclear positivity (1+) Figure S5. Heterogeneity of ER expression within the cultured MCF-7 human breast cancer cell line. Cell line Staining 01+2+3+ MCF-7* + ER PE Ab15%18%67%0% Cells were cultured in hormone depleted media for 48 hours, harvested, and spiked into 7.5 ml of normal human blood. The blood was then processed using CellSearch® and stained for DAPI, CK, CD45, and ER. Examples of strong (2+, 3+), weak (1+), and no staining (0) are displayed. Apparent staining in the bottom panel is due to high gain analysis by the automated fluorescent microscopy, as indicated by very high background.

12 Average CTC/7.5 ml WB Coefficient of variation Figure. S6. Coefficient of variation of CTC-enumeration by mean CTC count.

13 ER staining Primary Tumor (IHC >95%), 200X ER staining in CTC 1+ 0 3% 50% 11% 36% IF Score % Cells 53% ER positive 47% ER negative Figure. S7. Heterogeneity between primary tissue and CTC for patient #4. The CTC galleries displayed were selected from over 1,000 images to illustrate CTC-ER heterogeneity. Composite DAPI Cytokeratin-FITC ER-PE CD45-APC 3+ 2+

Download ppt "“Learning curve” group= 10 pts with mBrCa (ER+ or ER-) who are beginning a new therapy ~5 pts with ≥5CTC/7.5 ml Group 1 5 CTC evaluable pts* with ER+ mBrCa."

Similar presentations

Tumor CompartmentStromal Compartment mask C D EF A B Supplemental Fig 1. Epithelial and stromal PD-L1 expression. AQUA scores for PD-L1 in the epithelium.

Tumor CompartmentStromal Compartment mask C D EF A B Supplemental Fig 1. Epithelial and stromal PD-L1 expression. AQUA scores for PD-L1 in the epithelium.
Supplementary Figure 1. Example of cluster image using the CellSearch ® system. Composite DAPI Cytokeratin-FITC M30-PE CD45-APC.

Supplementary Figure 1. Example of cluster image using the CellSearch ® system. Composite DAPI Cytokeratin-FITC M30-PE CD45-APC.
Circulating Tumor Cells

Circulating Tumor Cells
Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.
Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.
Predictors of HER2 FISH amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis Maria Vittoria Dieci 1,

Predictors of HER2 FISH amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis Maria Vittoria Dieci 1,
Clinical Utility of CellSearch Richard A. Bender,MD,FACP Medical Director-Hematology/Oncology Quest Diagnostics Nichols Institute.

Clinical Utility of CellSearch Richard A. Bender,MD,FACP Medical Director-Hematology/Oncology Quest Diagnostics Nichols Institute.
Supplementary Figure 1. Supplementary Figure 2 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive 40 69 Negative 18 31 PR Positive.

Supplementary Figure 1. Supplementary Figure 2 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive Negative PR Positive.
Supplemental Figure 1 A. EpCAM Gating Strategy Top Row: Histogram showing unstained BT474 cells with low fluorescent intensity of the EpCAM specific PE.

Supplemental Figure 1 A. EpCAM Gating Strategy Top Row: Histogram showing unstained BT474 cells with low fluorescent intensity of the EpCAM specific PE.
ER  HSP90 DMSO 200  M I3C30  M DIM200  M TRYPTOPHOL Supplemental Figure 1. DIM and Tryptophol fail to induce the downregulation of ER  seen with I3C.

ER  HSP90 DMSO 200  M I3C30  M DIM200  M TRYPTOPHOL Supplemental Figure 1. DIM and Tryptophol fail to induce the downregulation of ER  seen with I3C.
Pathology Reports Nicole Draper, MD.

Pathology Reports Nicole Draper, MD.
Microtube Device for Selectin- Mediated Capture of Viable Circulating Tumor Cells from Blood A.D. Hughes, J. Mattison, L.T. Western, J.D. Powderly, B.T.

Microtube Device for Selectin- Mediated Capture of Viable Circulating Tumor Cells from Blood A.D. Hughes, J. Mattison, L.T. Western, J.D. Powderly, B.T.
Ki67 SPATIAL DISTRIBUTION Ki67 PROLIFERATION REOXYGENATION 48 hours SUPPLEMENTARY FIGURES S1ABC Figure S1. Reoxygenation and Repopulation at 48 hours in.

Ki67 SPATIAL DISTRIBUTION Ki67 PROLIFERATION REOXYGENATION 48 hours SUPPLEMENTARY FIGURES S1ABC Figure S1. Reoxygenation and Repopulation at 48 hours in.
Postmenopausal breast cancer patients included in the original Stockholm tamoxifen trial (n=2459) Stockholm 2 cohort (n=679) Stockholm 3 cohort (n=1780)

Postmenopausal breast cancer patients included in the original Stockholm tamoxifen trial (n=2459) Stockholm 2 cohort (n=679) Stockholm 3 cohort (n=1780)
“Isolation of rare circulating tumour cells in cancer patients by microchip technology” Nagrath et al. Nature 2007 Peter Bojo.

“Isolation of rare circulating tumour cells in cancer patients by microchip technology” Nagrath et al. Nature 2007 Peter Bojo.
Supplementary Table 1: Clinicopathologic characteristics of 100 patients with invasive breast cancer Clinical characteristicsNumber of cases (%) Median.

Supplementary Table 1: Clinicopathologic characteristics of 100 patients with invasive breast cancer Clinical characteristicsNumber of cases (%) Median.
Ab hg fe d c Supplementary Figure 1 Supplementary figure 1: Validation of the ERRα antibody used for immunohistochemical analysis. Control MCF7 breast.

Ab hg fe d c Supplementary Figure 1 Supplementary figure 1: Validation of the ERRα antibody used for immunohistochemical analysis. Control MCF7 breast.
Supplemental Figure 1. Specificity of CCL2 and Fsp1 immunostaining of breast tumor tissues. Sections of invasive ductal carcinoma were incubated with primary.

Supplemental Figure 1. Specificity of CCL2 and Fsp1 immunostaining of breast tumor tissues. Sections of invasive ductal carcinoma were incubated with primary.
SpecimenCTCTissue MarkerAntibodySourceAntibodySource ER monoclonal murine ER- 119.3 Janssen Diagnostics, LLC monoclonal murine, clone 1D5, 1:50, high pH.

SpecimenCTCTissue MarkerAntibodySourceAntibodySource ER monoclonal murine ER Janssen Diagnostics, LLC monoclonal murine, clone 1D5, 1:50, high pH.
Circulating tumor cell monitoring, isolation and culture from a patient with metastatic triple negative breast cancer for drug screening and creation of.

Circulating tumor cell monitoring, isolation and culture from a patient with metastatic triple negative breast cancer for drug screening and creation of.

Similar presentations

Ads by Google